Kev Hloov Pauv ntawm Tib Neeg ROS1 Fusion Gene

ROS1 yog ib qho transmembrane tyrosine kinase ntawm tsev neeg insulin receptor. ROS1 fusion gene tau lees paub tias yog lwm qhov tseem ceeb ntawm cov qog nqaij hlav tsis yog me me hauv lub ntsws. Ua tus sawv cev ntawm ib qho tshiab tshwj xeeb molecular subtype, qhov tshwm sim ntawm ROS1 fusion gene hauv NSCLC Kwv yees li 1% txog 2% ROS1 feem ntau dhau los ntawm kev hloov pauv gene hauv nws cov exons 32, 34, 35 thiab 36. Tom qab nws tau sib xyaw nrog cov noob xws li CD74, EZR, SLC34A2, thiab SDC4, nws yuav txuas ntxiv mus ua kom ROS1 tyrosine kinase cheeb tsam ua haujlwm. ROS1 kinase ua haujlwm tsis zoo tuaj yeem ua kom cov kev taw qhia downstream xws li RAS / MAPK / ERK, PI3K / Akt / mTOR, thiab JAK3 / STAT3, yog li koom nrog kev loj hlob, kev sib txawv thiab metastasis ntawm cov hlwb qog, thiab ua rau mob qog noj ntshav. Ntawm ROS1 fusion mutations, CD74-ROS1 suav txog li 42%, EZR suav txog li 15%, SLC34A2 suav txog li 12%, thiab SDC4 suav txog li 7%. Cov kev tshawb fawb tau qhia tias qhov chaw ATP-binding ntawm catalytic domain ntawm ROS1 kinase thiab ATP-binding site ntawm ALK kinase muaj homology txog li 77%, yog li ALK tyrosine kinase me me molecule inhibitor crizotinib thiab lwm yam muaj cov nyhuv curative hauv kev kho mob ntawm NSCLC nrog fusion mutation ntawm ROS1. Yog li ntawd, kev kuaj pom ntawm ROS1 fusion mutations yog lub hauv paus thiab lub hauv paus rau kev coj siv cov tshuaj crizotinib.